According to a report from Naver News on July 16, the world's largest tobacco company, Philip Morris International, plans to reintroduce its HNB product "IQOS" in the United States. This has sparked widespread concern from American health organizations, who are seriously worried about the potential harm of e-cigarettes and are urging regulatory agencies to proceed with caution in approving these products.
Six health organizations, including the American Academy of Pediatrics, the American Lung Association, and the Campaign for Tobacco-Free Kids, have sent a letter of protest to the U.S. Food and Drug Administration (FDA) expressing concerns about the re-entry of IQOS e-cigarettes to the market. These organizations point out that despite claims from Philip Morris International that IQOS helps with smoking cessation, existing evidence shows that the product is not as effective in helping people quit smoking as advertised.
The protest letter mentioned that Philip Morris International has repeatedly made potentially misleading statements that led the public to believe that the FDA had confirmed that IQOS can reduce the risk of illness. Additionally, the letter pointed out that the implication that IQOS is less harmful than traditional cigarettes violates FDA regulations. Furthermore, the health organizations stated that Philip Morris International's claims that IQOS can prompt a large number of traditional smokers to switch to e-cigarettes lack factual basis. They cited research data from the International Tobacco Control Project (ITC) at the University of Waterloo in Canada, showing that the smoking cessation rates for IQOS users in South Korea and Japan are 30% and 15%, respectively, far below the 70% claimed by Philip Morris International.
In response, Philip Morris International stated that the company always abides by relevant laws and regulations when discussing science and products, and insists that their statements comply with FDA regulations. The FDA had approved the sale of the older version of IQOS by Philip Morris International in 2019, but later issued a "risk modification" order requiring the company to improve the product to reduce emissions of harmful chemicals. Last year, Philip Morris International applied to introduce the latest modified version of IQOS, but the FDA has not yet made a decision on whether to approve its market release.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
